FDA's device review 
program, including PMAs. FDA, in consultation with the regulated 
industry, agreed to dedicate user fees to helping the agency meet the 
performance goals outlined in a letter from the Secretary of Health and 
Human Services to Congress that accompanied the user fee legislation. 
One such goal included a commitment to ``improve the scheduling and 
timeliness of preapproval inspections.'' A portion of the user fees 
collected under MDUFMA will be used to help to cover the costs 
